Antifungal drug delays need for chemo in advanced prostate cancer

June 2, 2011 in Cancer

The oral antifungal drug itraconazole, most commonly used to treat nail fungus, may keep prostate cancer from worsening and delay the need for chemotherapy in men with advanced disease. Details of the finding, from a clinical trial led by Johns Hopkins experts, are scheduled for presentation on Saturday, June 4 at the 2011 American Society of Clinical Oncology (ASCO) annual meeting (abstract #4532).

Currently, the drug is approved to treat fungal infections in nails and other organs. Serious side effects can include , and Johns Hopkins experts caution that needs further study before it can be considered for .

Identified as a potential after Hopkins scientists scoured a database of more than 3,000 FDA-approved drugs, itraconazole appears to block tumor -- the only drug in its class to do so -- much like the anticancer drug (). The antifungal also disrupts a key cancer-initiating biological pathway called Hedgehog. Laboratory testing by Johns Hopkins scientist Jun Liu, Ph.D., has shown that human implanted in mice shrink when treated with itraconazole.

"The most we have right now for metastatic prostate cancer is hormone therapy, and when it doesn't work, the next step is usually chemotherapy," says Emmanuel Antonarakis, M.D., assistant professor of oncology at the Johns Hopkins Kimmel Cancer Center. In a search for compounds that could put off chemotherapy, the Johns Hopkins team turned to itraconazole.

For the study, patients with prostate cancer that had spread to other organs and did not respond to hormone therapy were randomly assigned to receive low or high doses of itraconazole.

Over 24 weeks of daily treatment with oral itraconazole, the investigators tracked the length of time for each patient's prostate cancer to worsen (called progression-free survival). Evidence of worsening disease was measured by a 25 percent increase in their blood level of prostate specific antigen (PSA), a marker for prostate cancer.

Early in the trial, preliminary analysis of 17 men receiving low doses of itraconazole showed that only two of them (11.8 percent) had stable or declining PSA. Because of the limited response, no further men were given low doses of the drug.

However, 11 of 24 (48.4 percent) men taking high doses of itraconazole had stable or declining PSA levels lasting at least 24 weeks. In addition, nearly a third of men taking the high dose had PSA reductions of 30 percent or more. Metastatic prostate cancer patients receiving no treatment typically would worsen in eight to 12 weeks, according to Antonarakis.

The investigators also found that 12 of 14 men taking high doses of itraconazole had lower levels of circulating tumor cells present in their blood after therapy, compared with their baseline levels.

Seven patients experienced side effects, including low potassium, hypertension and fluid retention, but the problems were resolved with potassium replacement pills, anti-hypertension drugs, and diuretics.

"We also tested whether itraconazole acted as hormone therapy by tracking levels of testosterone and DHEA (a testosterone derivative) in the blood, and we found no reductions of either testosterone or DHEA," says Antonarakis. "This finding shows that itraconazole is not just another hormone therapy, and has a unique mechanism of action."

Antonarakis and colleagues next plan to examine blood and skin samples taken from study participants specifically to look for levels of proteins linked to tumor blood vessel formation and the Hedgehog pathway.

"With these results, we believe that high-dose itraconazole is worth studying in a larger group of men with advanced ," adds Antonarakis.

Provided by Johns Hopkins Medical Institutions

not rated yet  

Rank not rated yet
Relevant PhysicsForums posts
  • A question about drug tolerance
    created20 hours ago
  • Poor nutrition leading to overeating?
    createdMay 23, 2012
  • Math and dyslexia?
    createdMay 21, 2012
  • portable metabolism meter?
    createdMay 21, 2012
  • Rare medical conditions on 20/20 tonight
    createdMay 18, 2012
  • "Good" Cholesterol in Doubt
    createdMay 17, 2012
  • More from Physics Forums - Medical Sciences

More news stories

Marked for destruction: Newly developed compound triggers cancer cell death

The BCL-2 protein family plays a large role in determining whether cancer cells survive in response to therapy or undergo a form of cell death known as apoptosis. Cells are pressured toward apoptosis by expression of pro-apoptotic ...

Cancer created 3 hours ago | popularity 5 / 5 (1) | comments 0

Thioridazine kills cancer stem cells in human while avoiding toxic side-effects of conventional cancer treatments

A team of scientists at McMaster University has discovered a drug, thioridazine, successfully kills cancer stem cells in the human while avoiding the toxic side-effects of conventional cancer treatments.

Cancer created 3 hours ago | popularity 4.3 / 5 (3) | comments 1 | with audio podcast

Study links mental health problems to poor prognosis in male cancer patients

Men suffering from psychiatric problems when diagnosed with cancer are more likely to die from the disease, according to a new study part-funded by the Wellcome Trust. The findings also reveal that those with ...

Cancer created 6 hours ago | popularity not rated yet | comments 0

Cancer docs often deal with own grief, doubts when patients die

(HealthDay) -- Some cancer doctors may build up emotional walls -- distancing themselves from the patients they can't save -- to avoid grief, sadness and even despair, new research shows.

Cancer created May 23, 2012 | popularity not rated yet | comments 0 | with audio podcast

Regorafenib active in metastatic GI stromal tumors

(HealthDay) -- Regorafenib, an inhibitor of multiple cancer-associated kinases, is active in patients with metastatic gastrointestinal stromal tumors (GIST) who have failed to respond to imatinib and sunitinib, ...

Cancer created May 23, 2012 | popularity not rated yet | comments 0


Researchers identify protein necessary for behavioral flexibility

Researchers have identified a protein necessary to maintain behavioral flexibility, which allows us to modify our behaviors to adjust to circumstances that are similar, but not identical, to previous experiences. Their findings, ...

Boundary stops molecule right where it needs to be

A molecule responsible for the proper formation of a key portion of the nervous system finds its way to the proper place not because it is actively recruited, but instead because it can't go anywhere else.

Researcher calls for new approach to regulating probiotics

In today's Nature scientific journal Dr. Gregor Reid, Director of the Canadian R&D Centre for Probiotics at Lawson Health Research Institute and a scientist at Western University, calls for a Category Tree system to be imp ...

Male fertility genes discovered

A new study has revealed previously undiscovered genetic variants that influence fertility in men. The findings, published by Cell Press on May 24th in the American Journal of Human Genetics, shed much-needed light on hum ...

Knowing genetic makeup may not significantly improve disease risk prediction

Harvard School of Public Health (HSPH) researchers have found that detailed knowledge about your genetic makeup—the interplay between genetic variants and other genetic variants, or between genetic variants and environmental ...

A boost in microRNA may protect against sepsis and other inflammatory diseases

Acute inflammatory diseases, such as sepsis, as well as chronic inflammatory diseases like diabetes and arthritis, develop as a result of sustained inflammation of the blood vessel wall. Researchers at Brigham and Women's ...